Sonja M. Bragg

466 total citations
9 papers, 134 citations indexed

About

Sonja M. Bragg is a scholar working on Psychiatry and Mental health, Physiology and Genetics. According to data from OpenAlex, Sonja M. Bragg has authored 9 papers receiving a total of 134 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Psychiatry and Mental health, 3 papers in Physiology and 3 papers in Genetics. Recurrent topics in Sonja M. Bragg's work include Migraine and Headache Studies (3 papers), Inflammatory Bowel Disease (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Sonja M. Bragg is often cited by papers focused on Migraine and Headache Studies (3 papers), Inflammatory Bowel Disease (3 papers) and Chronic Lymphocytic Leukemia Research (2 papers). Sonja M. Bragg collaborates with scholars based in United States, Italy and Germany. Sonja M. Bragg's co-authors include Sherie A. Dowsett, Suzanne Klise, John H. Krege, Messoud Ashina, Erin Doty, Uwe Reuter, Timothy R. Smith, Qun Lin, AnnCatherine M. Downing and Scott W. Andersen and has published in prestigious journals such as Gastroenterology, Cephalalgia and Current Medical Research and Opinion.

In The Last Decade

Sonja M. Bragg

9 papers receiving 127 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sonja M. Bragg United States	6	68	57	40	30	29	9	134
Yingqi Shi United States	8	73 1.1×	60 1.1×	28 0.7×	9 0.3×	12 0.4×	20	219
Tengfei Wang United States	8	39 0.6×	31 0.5×	5 0.1×	43 1.4×	12 0.4×	18	198
J Boulliat France	8	37 0.5×	110 1.9×	8 0.2×	18 0.6×	36 1.2×	15	244
Н. П. Гарганеева Russia	6	33 0.5×	19 0.3×	16 0.4×	4 0.1×	16 0.6×	41	113
Jodie Lord United Kingdom	7	30 0.4×	63 1.1×	5 0.1×	48 1.6×	3 0.1×	12	160
Brenton A. Wright United States	8	27 0.4×	43 0.8×	8 0.2×	6 0.2×	3 0.1×	17	218
Loukas Zagkos United Kingdom	8	13 0.2×	23 0.4×	8 0.2×	52 1.7×	14 0.5×	22	179
Suzanne Curran United Kingdom	5	10 0.1×	40 0.7×	13 0.3×	25 0.8×	9 0.3×	6	346
Sandra Loves Netherlands	7	28 0.4×	48 0.8×	10 0.3×	39 1.3×	102 3.5×	9	311
Е. С. Филатова Russia	6	38 0.6×	28 0.5×	6 0.1×	3 0.1×	36 1.2×	51	128

Countries citing papers authored by Sonja M. Bragg

Since Specialization

Citations

This map shows the geographic impact of Sonja M. Bragg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sonja M. Bragg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sonja M. Bragg more than expected).

Fields of papers citing papers by Sonja M. Bragg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sonja M. Bragg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sonja M. Bragg. The network helps show where Sonja M. Bragg may publish in the future.

Co-authorship network of co-authors of Sonja M. Bragg

This figure shows the co-authorship network connecting the top 25 collaborators of Sonja M. Bragg. A scholar is included among the top collaborators of Sonja M. Bragg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sonja M. Bragg. Sonja M. Bragg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

D’Haens, Geert, Silvio Danese, Bruce E. Sands, et al.. (2024). 985 EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY. Gastroenterology. 166(5). S–238. 2 indexed citations

Sands, Bruce E., Silvio Danese, Minhu Chen, et al.. (2024). Su1801 PRIMARY EFFICACY AND SAFETY OF MIRIKIZUMAB IN MODERATE TO SEVERE CROHN'S DISEASE: RESULTS OF THE TREAT-THROUGH VIVID 1 STUDY. Gastroenterology. 166(5). S–820. 1 indexed citations

Jairath, Vipul, Bruce E. Sands, Peter Bossuyt, et al.. (2024). OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study. Journal of Crohn s and Colitis. 18(Supplement_1). i62–i64. 20 indexed citations

Ferrante, Marc, Silvio Danese, M Chen, et al.. (2024). OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. Journal of Crohn s and Colitis. 18(Supplement_1). i7–i9. 11 indexed citations

Charleston, Larry, et al.. (2022). Migraine history and response to lasmiditan across racial and ethnic groups. Current Medical Research and Opinion. 38(5). 721–730. 1 indexed citations

Tassorelli, Cristina, et al.. (2021). Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine. The Journal of Headache and Pain. 22(1). 14 indexed citations

Zimmer, Jennifer A., Sergey Shcherbinin, Michael D. Devous, et al.. (2021). Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease. Alzheimer s & Dementia Translational Research & Clinical Interventions. 7(1). e12123–e12123. 23 indexed citations

Ashina, Messoud, Uwe Reuter, Timothy R. Smith, et al.. (2021). Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 41(3). 294–304. 44 indexed citations

Sims, John R., Katherine J. Selzler, AnnCatherine M. Downing, et al.. (2017). Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814).. PubMed. 4(4). 247–254. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact